Lassa Fever, Marburg and Ebola Virus

oPatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.

This page has been archived. It has not been updated since 25/08/2010. External links and references may no longer work.
These diseases are notifiable in the UK.

The viral haemorrhagic fevers (VHFs) are caused by four types of RNA virus:

  • Filoviruses cause Ebola haemorrhagic fever (HF) and Marburg HF
  • Arenaviruses cause Lassa fever, Argentine HF and Bolivian HF
  • Bunyaviruses cause Korean HF (Hantavirus), Rift Valley fever and Crimean-Congo HF
  • Flaviviruses cause yellow fever and dengue

Of these, Lassa fever, Marburg HF and Ebola HF are the most significant.

Save time & improve your PDP on Patient.co.uk

  • Notes Add notes to any clinical page and create a reflective diary
  • Track Automatically track and log every page you have viewed
  • Print Print and export a summary to use in your appraisal
Click to find out more »

Infected dendritic cells are largely impaired in their activation potency, likely contributing to the immune suppression that occurs during filovirus infection. Monocytes/macrophages, however, immediately activate after viral contact and release reasonable amounts of cytokines that target the vascular system, particularly the endothelial cells.[1] Fibroblastic reticular cells, another prevalent infected cell type, are known to be a key regulator of circulatory and immune functions.[2] Similar processes are thought to occur in arenavirus infection.[3]

These three diseases are almost invariably found in Central Africa where outbreaks are usually sporadic but very infectious and have a very high mortality rate. A study in Gabon showed that 6% of the population had had contact with Ebola HF[4] but not Marburg HF or Lassa fever. Cases imported from endemic areas have been reported sporadically in the United Kingdom. [5][6]

  • Lassa fever affects between 300,000 and 500,000 people annually in West Africa, of whom about 5,000 die.[7]
  • Probably 80% of Lassa fever is subclinical but in the other 20% it can take a complicated course. Subclinical infection with Marburg or Ebola virus is much rarer.
  • Ebola HF outbreaks are more sporadic but mortality is 50-90%.[8]
  • Marburg HF outbreaks are also sporadic. There have been recent ones in the Congo and Angola. Deaths in Europe have occurred in laboratory workers who handled green monkeys.[9]

There is no apparent difference in predilection between sex and races.

  • Lassa fever is transmitted directly to humans by rodents, insect bites (especially mosquito), primates and patients.
  • Marburg HF originated from a group of African green monkeys imported from Uganda but the usual vector for Ebola and Marburg HF is not known.
  • There is transmission between humans in all three diseases. This tends to be from body fluids rather than droplet spread.
  • In some African hospitals needles are used for more than one patient, patients may share beds and soiled sheets can transmit disease. This is called nosocomial infection and is a major cause of spread.[10]
  • Doctors and nurses who operate on infected patients are at risk.

In recent years some new VHFs have emerged in various parts of the world, usually where human habitation has encroached on rain forests.

It is said that both the USA and the former USSR developed the VHF viruses, especially Lassa, Marburg and Ebola, for use in biological warfare. Conceivably other states and terrorist organisations could do the same[11] and the lack of familiarity with such diseases would increase the risk.[12]

  • The incubation period is 4 to 21 days.
  • Symptoms start with fever, headaches, myalgia and conjunctival suffusion.
  • On about the fifth day of illness, a maculopapular rash may appear, mostly on the trunk.

Many systems are affected:

Gastrointestinal tract

  • Nausea and vomiting (perhaps bloody)
  • Diarrhoea (bloody)
  • Abdominal pain
  • Constipation
  • Dysphagia
  • Hepatitis with jaundice or pancreatitis

Cardiovascular system

Respiratory tract

  • Cough
  • Chest pain
  • Dyspnoea
  • Pharyngitis

Nervous system

  • Encephalitis
  • Meningitis
  • Unilateral or bilateral deafness (usually Lassa fever)
  • Seizures

Bleeding occurs in the nose, intestines or genitalia. Symptoms may increase in severity with rapid weight loss, prostration, delirium, shock, hepatic failure, massive haemorrhage and multi-organ failure. Bleeding is a less notable feature of Lassa fever than the others.

The disease is usually fatal within a few days.

This is mostly between the various other VHFs. Serological tests can establish the exact cause and strain.

Note: keep investigations to a minimum to protect laboratory staff and handle all specimens with extreme care.

Non-drug

Treatment is symptomatic. Attention to hydration and blood loss may be required with IV fluids, blood, plasma and platelets. Oxygen may be needed.

Secondary prevention requires total isolation of affected patients.

Drugs

  • No effective treatments, prophylactic measures, therapies or vaccines are approved to treat or prevent Ebola HF and Marburg HF.[13]
  • Lassa fever, South American HFs and possibly Crimean-Congo fever and Rift Valley HF may be treated by a slow intravenous infusion of ribavirin.
  • Adults require a loading dose of 2 grams (30 mg/kg) followed by 1 gram (15 mg/kg) every six hours for four days, followed by 500 mg (7.5 mg/kg) every eight hours for six days.
  • The dose in children is uncertain.
  • It should be started as soon as possible; however, the cost of this drug in Central African countries is often prohibitive.

Analgesics and antipyretics may be required. Avoid aspirin and IM injections because of bleeding.

  • Hepatic failure is more common in Marburg HF and Ebola HF, as is DIC.
  • In pregnancy, fetal loss exceeds 80%.
  • Deafness occurs in 25% of cases of Lassa fever, with half recovering some hearing after 3 months.
  • Acute kidney injury is an uncommon complication of VHF but acute renal dysfunction has been reported.[14]
  • Marburg HF has a mortality rate around 25%. Ebola HF kills between 50 and 90%.[8]
  • There are five different strains of Ebola HF: Bundibugyo, C(te d'Ivoire, Reston, Sudan and Zanre. Ebola Zaire is the deadliest known strain of the virus with a mortality rate as high as 90%.
  • In Lassa fever, of those who are admitted to hospital, about 15 to 20% die, giving an overall mortality of between 1 and 3%; however, in epidemics it can be up to 50%. Mortality tends to be higher in children and the elderly. It is more severe if contracted from a patient.
  • Those who recover from these infections have long-lasting immunity but life-long immunity has not been demonstrated.
  • Of the various haemorrhagic fevers, only yellow fever has a vaccine. A vaccine against Lassa fever[15] and Ebola HF[16] may not be far off.
  • A vaccine for Marburg HF is being developed.[17]
  • Patients are infectious as long as they are pyrexial but corpses are also infectious.
  • Keep away from vectors such as rodents or infected primates. Control rodent populations, prevent them from entering homes and workplaces and clean up droppings. Avoid mosquito bites - along the same principles as with malaria. When treating patients use gloves, gowns, masks and goggles, as infection acquired from patients seems to be particularly virulent.
  • Close surveillance of contacts for 3 weeks with isolation if they become pyrexial.

Further reading & references

  1. Aleksandrowicz P, Wolf K, Falzarano D, et al; Viral haemorrhagic fever and vascular alterations. Hamostaseologie. 2008 Feb;28(1-2):77-84.
  2. Steele KE, Anderson AO, Mohamadzadeh M; Fibroblastic reticular cells and their role in viral hemorrhagic fevers. Expert Rev Anti Infect Ther. 2009 May;7(4):423-35.
  3. Baize S, Kaplon J, Faure C, et al; Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J Immunol. 2004 Mar 1;172(5):2861-9.
  4. Ivanoff B, Duquesnoy P, Languillat G, et al; Haemorrhagic fever in Gabon. I. Incidence of Lassa, Ebola and Marburg viruses in Haut-Ogooue. Trans R Soc Trop Med Hyg. 1982;76(6):719-20.
  5. Atkin S, Anaraki S, Gothard P, et al; The first case of Lassa fever imported from Mali to the United Kingdom, February 2009. Euro Surveill. 2009 Mar 12;14(10). pii: 19145.
  6. Kitching A, Addiman S, Cathcart S, et al; A fatal case of Lassa fever in London, January 2009. Euro Surveill. 2009 Feb 12;14(6). pii: 19117.
  7. World Health Organisation; Lassa fever; fact sheet
  8. World Health Organisation; Ebola; fact sheet
  9. World Health Organisation; Marburg haemorrhagic fever; fact sheet
  10. Speed BR, Gerrard MP, Kennett ML, et al; Viral haemorrhagic fevers: current status, future threats. Med J Aust. 1996 Jan 15;164(2):79-83.
  11. Pigott DC; Hemorrhagic fever viruses. Crit Care Clin. 2005 Oct;21(4):765-83, vii.
  12. Borio L, Inglesby T, Peters CJ, et al; Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA. 2002 May 8;287(18):2391-405.
  13. Gene OG, Julia BE, Vanessa MR, et al; Drug targets in infections with Ebola and Marburg viruses. Infect Disord Drug Targets. 2009 Apr;9(2):191-200.
  14. Lima EQ, Nogueira ML; Viral hemorrhagic fever-induced acute kidney injury. Semin Nephrol. 2008 Jul;28(4):409-15.
  15. Lukashevich IS, Patterson J, Carrion R, et al; A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol. 2005 Nov;79(22):13934-42.
  16. Martin JE, Sullivan NJ, Enama ME, et al; A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. 2006 Nov;13(11):1267-77. Epub 2006 Sep 20.
  17. Bausch DG, Geisbert TW; Development of vaccines for Marburg hemorrhagic fever. Expert Rev Vaccines. 2007 Feb;6(1):57-74.

Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.

Original Author:
Dr Laurence Knott
Current Version:
Last Checked:
25/08/2010
Document ID:
2371 (v24)
© EMIS